Related to Ipsen Drops Irosustat Monotherapy Program in Cancer but Will Evaluate Combination Therapy Options

• Triple Threat: Gene Controls Three Diseases
  
• Turning Off Cancer’s “Master Regulator”
  
• Sorrento, Igdrasol Secure Exclusive E.U. Distribution Rights to Cancer Drug
  
• Bayer Prostate Cancer Drug Gains FDA Approval
  
• Empire Genomics Nabs Prostate Cancer Biomarker from Cornell
  
• Oncothyreon Joins Array in Developing Cancer Compound
  
• Isis Wins $10M After AstraZeneca Adds Prostate Cancer Drug to Collaboration
  
• Study: Genetic Testing Uptake within Cancer-Affected Families Remains Low
  
• Supreme Court Upends Patentability of Genes, but Not cDNA
  
• J&J Acquiring Aragon for Up To $1B
  
• Nine European Countries Sanction Six-Month Formulation of Debiopharm’s Prostate Cancer Medication
  
• French Authorities Approve Six-Month Formulation of Debiopharm and Ipsen’s Prostate Cancer Drug
  
• GTx and Ipsen Expand Toremifene Partnership to Encompass FDA’s Requested 2nd Phase III Trial
  
• GTx and Ipsen Fail to Show Benefit of Toremifene 20 mg in Prostate Cancer
  
• The Research Foundation of SUNY to Help Sunshine Biopharma Push Anticancer Agent into the Clinic
  
• GTx and Ipsen End Prostate Cancer Collaboration due to Costs of FDA-Requested Phase III Study
  
• Active Biotech Receives €25M Up Front from Ipsen as Part of Cancer Deal
  
• Hanmi Licenses Kinex’ Phase II Anticancer Candidate in Select Asian Countries
  
• Aragon Raises $42M to Progress Prostate and Breast Cancer Drugs
  
• Major Advance: Novel DNA Cancer-Associated Variants Identified